Thursday, April 27, 2023, San Antonio, Texas, 12:15 PM – 1:45 PM Central Time (1:15 PM – 2:45 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Chronic Lymphocytic Leukemia

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Lunch Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
John N Allan, MD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
New York, New York

Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC
Family Nurse Practitioner
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner, Hematology
The James Comprehensive Cancer Center
The Ohio State University Wexner Medical Center
Columbus, Ohio

Adam S Kittai, MD
Assistant Professor
Division of Hematology
The Ohio State University
The OSUCCC – James
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Educational Lunch Meeting

What I Tell My Patients About ...

The Relevance of Biomarker Testing in Chronic Lymphocytic Leukemia (CLL)

  • Implications of various biomarkers, such as IGHV, del(17p) and TP53 mutations, for prognosis and therapeutic selection
  • Methods for biomarker assessment and current indications for testing
  • Role of repeat biomarker testing for patients with progressive disease

First-Line Therapy for Newly Diagnosed CLL

  • Available clinical trial data documenting the efficacy and safety of ibrutinib, acalabrutinib and zanubrutinib for newly diagnosed CLL
  • Implications for up-front decision-making of published results from Phase III studies comparing acalabrutinib or zanubrutinib to ibrutinib for previously treated CLL
  • Outcomes observed with venetoclax-based up-front regimens for treatment-naïve CLL
  • Advantages and limitations of indefinite versus time-limited up-front therapy

The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL

  • Relevant patient comorbidities, such as hypertension, chronic kidney disease and need for anticoagulation, that might influence clinical decision-making for CLL
  • Probability of stroke or other thromboembolic and bleeding events with Bruton tyrosine kinase (BTK) inhibitor therapy; data documenting the increase in risk with concomitant anticoagulation therapy
  • Documented interactions between BTK inhibitors or venetoclax and other prescription drugs or over-the-counter medications and supplements
  • Incidence of polypharmacy among patients with CLL and impact on adherence to oral therapy

Toxicities and Other Practical Considerations with BTK Inhibitors

  • Similarities and differences among ibrutinib, acalabrutinib and zanubrutinib and implications for the incidence and severity of class-related and agent-specific toxicities
  • Data documenting the comparative tolerability of ibrutinib, acalabrutinib and zanubrutinib
  • Risk factors for and reported incidence and severity of cardiac arrhythmias, including atrial fibrillation, with ibrutinib, acalabrutinib or zanubrutinib; optimal monitoring and management algorithms
  • Spectrum, incidence and management of clinically relevant nonhematologic toxicities with BTK inhibitors, such as arthralgias and myalgias, gastrointestinal events, cytopenias, infections and rash
  • Practical ramifications of the recent FDA approval of the tablet formulation of acalabrutinib

The Tolerability and Duration of Venetoclax-Based Treatment

  • Incidence of tumor lysis syndrome (TLS) with venetoclax; key risk factors
  • Guideline and expert recommendations for hospitalization of patients before commencing venetoclax; approaches to monitoring for and managing laboratory and clinical TLS
  • Spectrum, incidence, severity and management of other toxicities reported with venetoclax, such as neutropenia, infections and gastrointestinal disorders
  • Definition and clinical significance of minimal residual disease (MRD)
  • Current role, if any, of MRD assessment in CLL and implications for the duration of venetoclax-based treatment

The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax

  • Rationale for combining BTK inhibitors, venetoclax and/or anti-CD20 antibodies for CLL
  • Phase III efficacy and safety findings with the combination of ibrutinib and venetoclax as first-line treatment for CLL; potential role of this strategy
  • Available data sets with acalabrutinib and zanubrutinib in combination with venetoclax with or without an anti-CD20 antibody
  • Ongoing Phase III studies assessing novel doublet and triplet combinations for previously untreated and relapsed/refractory (R/R) disease
  • Incidence and severity of clinically relevant toxicities encountered when combining BTK inhibitors and venetoclax

Available Therapies for R/R CLL and Promising Investigational Agents and Strategies

  • Long-term data with BTK inhibitors and venetoclax for R/R CLL; role of rechallenge with agents used in a prior line of therapy
  • Antitumor activity documented with pirtobrutinib for patients with R/R CLL, including those with disease progression on covalent BTK inhibitors
  • Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
  • Biologic rationale for and early clinical trial experience with CD19-directed chimeric antigen receptor T-cell therapy for CLL

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and explain to patients the risks and potential benefits of time-limited therapy.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL, and provide corresponding education to patients.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/CLL/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr AllanConsulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc; Nonpromotional Disease State Awareness Speaking: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Broadway-DurenAdvisory Roles: AbbVie Inc, Pharmacyclics LLC, an AbbVie Company. Ms HoffmanAdvisory Board: BeiGene Ltd, Pharmacyclics LLC, an AbbVie Company. Dr KittaiAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Kite, A Gilead Company, Lilly; Consulting Agreement: AbbVie Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: BeiGene Ltd.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:45 AM Central Time on Thursday, April 27th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.